VivArt-X has been selected as one of 12 Dutch medtech companies to participate in the TMC Netherlands BioBridge Program 2026. The program supports ambitious Dutch medtech companies in preparing for and accelerating their expansion into the U.S. healthcare market.

Through the program, VivArt-X gains direct access to the Texas Medical Center (TMC) in Houston and its leading hospitals, clinicians, researchers and healthcare decision-makers. Participants also receive one-on-one mentoring from experienced entrepreneurs and gain opportunities to connect with potential production partners, customers and investors.

In addition, the program provides access to the TMC Innovation Factory, including accelerators, pilots and opportunities for clinical validation, as well as the Global Innovators Launch Pad. This program focuses on key aspects of U.S. market entry, including regulation, clinical evidence, reimbursement, funding and building a strong market-entry strategy.

Starting October 2026, the cohort consists of Aliform, Ansana, Clear.bio, Flux Robotics, Implant Preservation Devices, MindAffect, MLA Diagnostics, NBCL, ShanX Medtech, SLAM Orthopedic, Spatium Medical and VivArt-X.

The TMC Netherlands BioBridge Program is part of the collaboration between Texas Medical Center and the Dutch Life Sciences & Health ecosystem and is organized by Invest International, the Netherlands Enterprise Agency (RVO), NBSO Texas, Health~Holland, Task Force Health Care and ROM Nederland.